151 related articles for article (PubMed ID: 8978294)
1. Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules.
Guarini A; Riera L; Cignetti A; Montacchini L; Massaia M; Foa R
Blood; 1997 Jan; 89(1):212-8. PubMed ID: 8978294
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures.
Cignetti A; Guarini A; Gillio Tos A; Reato G; Foa R
Cancer Gene Ther; 2000 Feb; 7(2):167-76. PubMed ID: 10770624
[TBL] [Abstract][Full Text] [Related]
3. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
4. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
5. MHC class I ligation of human T cells activates the ZAP70 and p56lck tyrosine kinases, leads to an alternative phenotype of the TCR/CD3 zeta-chain, and induces apoptosis.
Skov S; Bregenholt S; Claesson MH
J Immunol; 1997 Apr; 158(7):3189-96. PubMed ID: 9120273
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes.
Arienti F; Sulé-Suso J; Melani C; Maccalli C; Belli F; Illeni MT; Anichini A; Cascinelli N; Colombo MP; Parmiani G
Hum Gene Ther; 1994 Sep; 5(9):1139-50. PubMed ID: 7833372
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
8. Expansion of CD3+CD56+ lymphocytes correlates with induction of cytotoxicity by interleukin-2 gene transfer in human breast tumor cultures.
Euhus DM; Kimura L; Arnold B
Ann Surg Oncol; 1997; 4(5):432-9. PubMed ID: 9259972
[TBL] [Abstract][Full Text] [Related]
9. Syk and ZAP-70 mediate recruitment of p56lck/CD4 to the activated T cell receptor/CD3/zeta complex.
Thome M; Duplay P; Guttinger M; Acuto O
J Exp Med; 1995 Jun; 181(6):1997-2006. PubMed ID: 7539035
[TBL] [Abstract][Full Text] [Related]
10. Human lung carcinoma cells engineered to release IL2, IL7, GM-CSF and TNF alpha.
Guarini A; Riera L; Reato G; Carbone A; Cignetti A; Tos A; Lanfrancone L; Melani C; Paul R; Forni G; Foa R
Int J Oncol; 1996 Apr; 8(4):765-72. PubMed ID: 21544424
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2.
Salvadori S; Zier K
J Immunol; 1996 Apr; 156(8):2927-32. PubMed ID: 8609413
[TBL] [Abstract][Full Text] [Related]
12. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
[TBL] [Abstract][Full Text] [Related]
13. IL-13 can substitute for IL-4 in the generation of dendritic cells for the induction of cytotoxic T lymphocytes and gene therapy.
Alters SE; Gadea JR; Holm B; Lebkowski J; Philip R
J Immunother; 1999 May; 22(3):229-36. PubMed ID: 10335482
[TBL] [Abstract][Full Text] [Related]
14. Gene transfer investigations of p56-LCK function in IL-2-dependent T-cell lines: implications for mechanisms of IL-2-signal transduction.
Taichman RS; Torigoe T; Tanaka S; Miyashita T; Reed JC
Cytokine; 1992 Nov; 4(6):441-53. PubMed ID: 1292628
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-specific activation of distinct mitogen-activated protein kinase subtype cascades in human neutrophils stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha.
Suzuki K; Hino M; Hato F; Tatsumi N; Kitagawa S
Blood; 1999 Jan; 93(1):341-9. PubMed ID: 9864179
[TBL] [Abstract][Full Text] [Related]
16. The regulation of phenotype and function of human liver CD3+/CD56+ lymphocytes, and cells that also co-express CD8 by IL-2, IL-12 and anti-CD3 monoclonal antibody.
Jin Y; Fuller L; Carreno M; Esquenazi V; Tzakis AG; Miller J
Hum Immunol; 1998 Jun; 59(6):352-62. PubMed ID: 9634197
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients.
Takahashi K; Saito S; Kamamura Y; Katakawa M; Monden Y
Cancer Immunol Immunother; 2000 Dec; 49(10):537-43. PubMed ID: 11129324
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma.
Hinkel A; Tso CL; Gitlitz BJ; Neagos N; Schmid I; Paik SH; deKernion J; Figlin R; Belldegrun A
J Immunother; 2000 Jan; 23(1):83-93. PubMed ID: 10687141
[TBL] [Abstract][Full Text] [Related]
19. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12.
Parney IF; Farr-Jones MA; Kane K; Chang LJ; Petruk KC
Can J Neurol Sci; 2002 Aug; 29(3):267-75. PubMed ID: 12195617
[TBL] [Abstract][Full Text] [Related]
20. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2.
Yamaguchi Y; Ohta K; Shimizu K; Minami K; Noma K; Hihara J; Toge T
Anticancer Res; 2001; 21(1B):669-77. PubMed ID: 11299824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
